Design, synthesis, anticancer evaluation and molecular docking study of novel 2,4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors

Cherukupalli, 2018, Bioorg. Chem., 79, 46, 10.1016/j.bioorg.2018.02.030 Malumbres, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nat. Rev. Cancer, 9, 153, 10.1038/nrc2602 Otto, 2017, Cell cycle proteins as promising targets in cancer therapy, Nat. Rev. Cancer, 17, 93, 10.1038/nrc.2016.138 Collins, 2007, Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery, The Cancer Handbook, 10.1002/9780470025079.chap96.pub2 Abonia, 2012, Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity, Eur. J. Med. Chem., 57, 29, 10.1016/j.ejmech.2012.08.039 Castillo, 2018, Application of a catalyst-free Domino Mannich/Friedel-Crafts alkylation reaction for the synthesis of novel tetrahydroquinolines of potential antitumor activity, Tetrahedron, 74, 932, 10.1016/j.tet.2017.12.049 Cohen, 2002, Protein kinases-the major drug targets of the twenty-first century, Nat. Rev. Drug Discov., 1, 309, 10.1038/nrd773 Santos, 2017, A comprehensive map of molecular drug targets, Nat. Rev. Drug Discov., 16, 19, 10.1038/nrd.2016.230 Gridelli, 2011, Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence, Lung Cancer, 71, 249, 10.1016/j.lungcan.2010.12.008 Horiuchi, 2012, Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways, Proc. Nat. Acad. Sci. USA, 109, 1019, 10.1073/pnas.1111317109 Morgan, 1995, Principles of CDK regulation, Nature, 374, 131, 10.1038/374131a0 Asghar, 2015, The history and future of targeting cyclin dependent kinases in cancer therapy, Nat. Rev. Drug Discov., 14, 130, 10.1038/nrd4504 Matsumoto, 2004, A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry, Science, 306, 885, 10.1126/science.1103544 Malumbres, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nature reviews cancer, 9, 153, 10.1038/nrc2602 Cai, 2006, AZ703, anImidazo[1,2-a]Pyridine inhibitor of cyclindependent kinases 1 and 2, induces E2F-1-Dependent apoptosis enhanced by Depletion of cyclin-dependent kinase 9, Cancer Res, 66, 435, 10.1158/0008-5472.CAN-05-1769 Kong, 2003, Cell cycle inhibitors for the treatment of cancer, Drugs Fut., 28, 881, 10.1358/dof.2003.028.09.761413 Tadesse, 2019, Cyclin dependent kinase 2 inhibitors in cancer therapy: an update, J. Med. Chem., 62, 4233, 10.1021/acs.jmedchem.8b01469 Hylsová, 2017, Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines, Eur. J. Med. Chem., 126, 1118, 10.1016/j.ejmech.2016.12.023 Pan, 2016, Inhibition of prostate cancer growth by solanine requires the suppression of cell cycle proteins and the activation of ROS/P38 signaling pathway, Cancer Med., 5, 3214, 10.1002/cam4.916 Mita, 2017, Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies, Br. J. Cancer., 117, 1258, 10.1038/bjc.2017.288 Reck, 2019, Phase II study of Roniciclib in combination with Cisplatin/Etoposide or Carboplatin/Etoposide as first-line therapy in patients with extensive-disease small cell lung cancer, J. Thorac. Oncol., 14, 701, 10.1016/j.jtho.2019.01.010 Pasha, 2012, Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor, Drug Met. Lett., 6, 33, 10.2174/187231212800229336 Tong, 2010, Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma, J. Clin. Oncol., 28, 3015, 10.1200/JCO.2009.26.1347 Fahmy, 2017, Synthesis of N-containing heterocycles via mechanochemical grinding and conventional techniques, Asian J, Chem., 29, 2679, 10.14233/ajchem.2017.20798 Fahmy, 2016, Multicomponent synthesis of 4-arylidene-2-phenyl-5(4H)-oxazolones (azlactones) using a mechanochemical approach, Chem. Cent. J., 10, 59, 10.1186/s13065-016-0205-9 Hemdan, 2016, Synthesis of some new heterocycles derived from novel 2-(1,3-dioxisoindolin-2-yl)benzoyl isothiocyanate, J. Het. Chem., 53, 487, 10.1002/jhet.2287 Hemdan, 2016, Use of phthalimidoacetyl isothiocyanate as a scaffold in the synthesis of target heterocyclic systems, and their antimicrobial assessment, Chemical and Pharmaceutical Bulletin, 64, 483, 10.1248/cpb.c16-00099 Wang, 2018, Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells, Bioorg. Med. Chem., 26, 3491, 10.1016/j.bmc.2018.05.024 Ibrahim, 2010, Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors, Eur. J. Med. Chem., 45, 1158, 10.1016/j.ejmech.2009.12.026 Ghorab, 2018, Design, synthesis and molecular modeling study of certain 4-Methylbenzenesulfonamides with CDK2 inhibitory activity as anticancer and radio-sensitizing agents, Bioorg. Chem, 80, 276, 10.1016/j.bioorg.2018.06.010 Cherukupalli, 2018, Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors, Bioorg. Chem., 79, 46, 10.1016/j.bioorg.2018.02.030 Diao, 2019, Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity, Eur. J. Med. Chem., 179, 196, 10.1016/j.ejmech.2019.06.055 Ibrahim, 2011, Design, synthesis and biological study of novel pyrido[2,3-d] pyrimidine as anti-proliferative CDK2 inhibitors, Eur. J. Med. Chem., 46, 5825, 10.1016/j.ejmech.2011.09.041 Abdelazeem, 2020, Synthesis, biological evaluation and kinase profiling of novel S-benzo[4,5]thiazolo[2,3-c][1,2,4]triazole derivatives as cytotoxic agents with apoptosis-inducing activity, J. Mol. Str., 1219, 10.1016/j.molstruc.2020.128567 Holla, 2002, New bis-aminomercaptotriazoles and bis-triazolothiadiazoles as possible anticancer agents, Eur. J. Med. Chem., 37, 511, 10.1016/S0223-5234(02)01358-2 Kamel, 2014, Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents, Eur. J. Med. Chem., 86, 75, 10.1016/j.ejmech.2014.08.047 Padmavathi, 2009, Ali-Shazia, Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles, Eur. J. Med. Chem., 44, 2106, 10.1016/j.ejmech.2008.10.012 Hemdan, 2012, Utility of phthalimidoacyl isothiocyanate in synthesis of quinazolines, benzoxazoles, benzimidazoles, 1,2,4-triazoles, and oxatriazepines, Phosphorus, Sulfur and Silicon and the Related Elements, 187, 181, 10.1080/10426507.2011.597804 El-Sayed, 2019, Synthesis, antiproliferative, and antioxidant evaluation of 2-pentylquinazolin-4(3H)-one(thione) derivatives with DFT study, Molecules, 24, 3787, 10.3390/molecules24203787 El-Sayed, 2019, Cytotoxic effects of newly synthesized heterocyclic candidates containing nicotinonitrile and pyrazole moieties on hepatocellular and cervical carcinomas, Molecules, 24, 1965, 10.3390/molecules24101965 Rizk, 2017, Synthesis of novel pyrazole derivatives as antineoplastic agent, J. Het. Chem., 54, 3358, 10.1002/jhet.2956 El-Naggar, 2019, Design, synthesis, and molecular docking study of novel heterocycles incorporating 1,3,4-thiadiazole moiety as potential antimicrobial and anticancer agents, Molecules, 24, 1066, 10.3390/molecules24061066 Othman, 2019, Novel phthalimide based analogues: Design, synthesis, biological evaluation, and molecular docking studies, J. Enz. Inh. Med. Chem., 34, 1259, 10.1080/14756366.2019.1637861 Nossier, 2015, Synthesis, anticancer evaluation and molecular modeling of some substituted thiazolidinonyl and thiazolyl pyrazole derivatives, Int. J. Pharm. Sci., 7, 353 Othman, 2020, Novel heterocyclic hybrids of pyrazole targeting dihydrofolate reductase: design, biological evaluation and in silico studies, J. Enz. Inh. Med. Chem., 35, 1491, 10.1080/14756366.2020.1791842 Pfeffer, 2018, Apoptosis: A target for anticancer therapy, Int. J. Mol. Sci., 19, 448, 10.3390/ijms19020448 Yip, 2008, BCL-2 family proteins and cancer, Oncogene, 77, 6398, 10.1038/onc.2008.307 Kassem, 2019, In vitro anticancer potentiality and molecular modelling study of novel amino acid derivatives based on N1,N3-bis-(1-hydrazinyl-1-oxopropan-2-yl)isophthalamide, J. Enz. Inh. Med. Chem., 34, 1247, 10.1080/14756366.2019.1613390 Amr, 2019, Design, synthesis, anticancer evaluation and molecular modeling of novel estrogen derivatives, Molecules, 24, 416, 10.3390/molecules24030416 Bettayeb, 2008, CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases, Oncogene, 27, 5797, 10.1038/onc.2008.191 Nossier, 2018, Kinase inhibitory activities and molecular docking of a novel series of anticancer pyrazole derivatives, Molecules, 23, 3074, 10.3390/molecules23123074